Reaction Biology supports the drug discovery community with epigenetic screening services since the first epigenetic inhibitor testing was required in the early 2000s. Ever since the very beginnings of epigenetic drug discovery, we increased our portfolio and still provide the largest coverage for epigenetic assays.
We provide a wide variety of epigenetic assay servicesfor drug discovery. Our epigenetic screening services include bromodomain and other reader domain assays, methyltransferase assays, demethylase assays, and more. Get in contact with our scientists to talk about your next epigenetic drug discovery project today.
Epigenetic enzymes control the mechanics of genetic expression, acting as "on" and "off" switches for the human genome. Malfunctions of these enzymes are implicated in many immunological and neurodegenerative conditions as well as cancer. We are dedicated to providing end-to-end service for epigenetic drug discovery covering all steps of the preclinical drug discovery process.
Reaction Biology offers biochemical and biophysical assays to study epigenetic reader domains. More than 100 assays are available for screening, lead optimization, or selectivity profiling for reader domain inhibitors.
Reaction Biology provides compound screening against IDH by measuring enzyme activity in a coupled system wherein NADPH produced in the initial reaction is a co-factor in the conversion of resazurin to fluorescent resorufin in a secondary reaction.